Why this study was different
Plenty of research links biological age to single diseases. But chronic conditions rarely arrive alone. A person with type 2 diabetes often later develops chronic kidney disease. Someone with a stroke often has heart problems too.
The researchers coined a simple term. Cardiovascular-kidney-metabolic disease, or CKMD, covers four conditions that travel together. Heart disease, stroke, type 2 diabetes, and chronic kidney disease.
When two or more of those pile up, that becomes multimorbidity. Add dementia and death, and you have a full disease journey.
A massive population lens
The team used UK Biobank data on 433,911 adults. They tracked people from healthy to their first CKMD diagnosis, then to multimorbidity, then to dementia, and finally to death.
They measured biological aging two ways. PhenoAge uses standard blood markers. KDM-BA uses a different statistical recipe built on similar data. Both try to turn routine labs into an age estimate.
Then came the analysis. A multistate model tracks how people move between health states over time. Think of it as a flowchart with arrows between boxes, with each arrow having its own risk.
Every arrow got longer and heavier for people with accelerated biological aging.
Moving from healthy to that first CKMD diagnosis, PhenoAge acceleration raised the risk by 24% per step. KDM-BA acceleration raised it by 16%. Moving from one CKMD to multimorbidity, both scores predicted a roughly 20% increase in risk.
The link with dementia was weaker but still there. People who already had multimorbidity and also had accelerated biological aging had a 13% higher risk of progressing to dementia.
The accelerators did not just raise risk. They also shortened the time between stages.
The years you cannot get back
Here is the plainer translation. For people moving through this disease chain, biological age acceleration shaved roughly one year off the gap between healthy and first diagnosis. It took another 1.75 years off the gap to multimorbidity.
Life expectancy felt the squeeze too. People with multimorbidity lost about 1.36 years of expected life under the PhenoAge measure. Those who progressed to dementia lost about 0.77 years more.
Small numbers at first glance. But across a population of millions, they translate into enormous burdens on families and healthcare systems.
The speedometer analogy
Think of biological age like the speedometer in your body. Calendar age is the odometer. The odometer just counts miles you have driven.
The speedometer, though, tells you how fast you are moving right now. Drive faster, and the odometer racks up miles quicker. In the same way, higher biological age acceleration seems to push disease progression forward.
The key insight. Two people with the same odometer reading can be going different speeds.
Where lifestyle fits in
The associations were not uniform. They changed based on age, physical activity, education, and overall lifestyle. That is actually encouraging news.
It suggests that biological aging is not fully locked in. Habits that affect blood markers, like exercise, sleep, and diet, may also influence the speedometer reading.
The effect was also stronger in people whose first chronic disease was cardiovascular disease or type 2 diabetes. Those appear to be pivot points where accelerated aging does the most damage.
Honest limits
This is observational research. It shows strong associations, not cause and effect. We cannot say from this study that slowing biological aging will reverse the disease chain.
UK Biobank participants also skew healthier and whiter than the broader population. The numbers may shift in other groups.
And biological age scores are moving targets. PhenoAge and KDM-BA are useful but imperfect proxies. Future versions will likely refine these estimates.
What you can do today
There is no approved clinic test that tells you "your PhenoAge is 62." Some research labs offer biological age estimates, but results vary.
The more practical path. Standard preventive steps still work. Blood pressure control, blood sugar management, regular movement, and treatment of early kidney or heart issues all affect the same markers that feed into these scores.
If you are middle-aged with one CKMD already, this study underscores the importance of tight follow-up. The second disease often drives the worst outcomes.
Researchers are now asking whether lifestyle programs or medications can meaningfully slow biological aging, and whether that slowing translates into fewer CKMD cases. Trials that test interventions using biological age as a marker are starting to appear.
If they work, the clinical idea is powerful. A middle-aged person could get a single lab-based score that says "act now," long before any disease shows up.
